Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Pastewski

Pulmonary Disease Palmetto Bay, FL Medical Doctor

NPI 1427253236 CMS profile 432379

9333 Sw 152Nd St, Palmetto Bay, FL 33157

Open in the dashboard

General payments

$15,935

243 records reported · program years 2019–2025

Research payments

$825

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,349,527 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Andrew Pastewski of Palmetto Bay, FL is reported in the CMS Open Payments database as having received $15,935 across 243 general payments and $825 in research payments paid to them. Separately, studies naming them as principal investigator received $1,349,527 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,354 66
2024 General $5,547 69
2023 General $2,850 55
2022 General $1,055 22
2022 Research $825 2
2021 General $603 16
2020 General $484 13
2019 General $41 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Pastewski
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Andrew Pastewski were reported at $5,354. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Andrew Pastewski Pulmonary Disease median Middle half National median
2019 $41 $377 $109–$1,340 $163
2020 $484 $230 $56–$907 $114
2021 $603 $269 $68–$1,072 $132
2022 $1,055 $390 $100–$1,457 $149
2023 $2,850 $419 $114–$1,659 $160
2024 $5,547 $476 $123–$1,818 $164
2025 $5,354 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $5,354 28 payments
  2. GlaxoSmithKline, LLC. $2,564 64 payments
  3. Pulmonx Corporation $1,607 10 payments
  4. Inspire Medical Systems, Inc. $1,447 19 payments
  5. AstraZeneca Pharmaceuticals LP $1,428 28 payments
  6. Insmed, Inc. $827 23 payments
  7. Regeneron Healthcare Solutions, Inc. $810 18 payments
  8. La Jolla Pharmaceutical Company $475 4 payments
  9. Amgen Inc. $374 13 payments
  10. Baxter Healthcare $199 7 payments
  11. Other $848 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,669 235 payments
  2. Consulting Fee $4,051 2 payments
  3. Travel and Lodging $1,082 4 payments
  4. Education $132 2 payments
Products named General payments · program years 2019–2025
  1. ZEPHYR ENDOBRONCHIAL VALVE $1,607 10 payments
  2. TRELEGY ELLIPTA $1,259 41 payments
  3. INSPIRE $1,229 18 payments
  4. DUPIXENT Immunology $1,084 24 payments
  5. FASENRA $726 14 payments
  6. Arikayce $711 22 payments
  7. NUCALA $675 16 payments
  8. DUPIXENT Inflammation And Immunology $583 13 payments
  9. GIAPREZA $475 4 payments
  10. TEZSPIRE $374 13 payments
  11. Other $3,380 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $825 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

435

Median for Pulmonary Disease: 936

Drug cost

$350,051

Median for Pulmonary Disease: $487,987

Branded share of claims

97.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 209 $162,223
Dupixent Pen Dupilumab Brand 34 $130,518
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 39 $25,740
Breo Ellipta Fluticasone/Vilanterol Brand 45 $22,091
Symbicort Budesonide/Formoterol Fumarate Brand 15 $3,352
Advair Diskus Fluticasone Propion/Salmeterol Brand 15 $2,923
Wixela Inhub Fluticasone Propion/Salmeterol Brand 30 $2,184
Albuterol Sulfate Hfa Albuterol Sulfate Brand 37 $943
Azithromycin Generic 11 $77

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$131,822

Medicare's payments for the services billed

Medicare patients

289

Average age 75

Services billed

1,016

133 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 63%
Diabetes 60%
Ischemic heart disease 60%
Chronic kidney disease 54%
COPD 51%
Depression 47%
Arthritis 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$652 34 —
FASENRA
$335 — —
TRELEGY ELLIPTA
$191 209 —
AIRSUPRA
$184 — —
TEZSPIRE
$173 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

245 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record